IMCR today

$31.65-$0.73 (-2.25%)close Nov 11, 2026

Trend

DailyDowntrend (confirmed)

4 hourStrong Bullish

1 hourAscending Triangle

15 minAscending Triangle

5 minStrong Bearish

Daily trend turns up above $31.28

Key levels

Resistance$35.19

Resistance$33.56

Support$31.28

Support$28.12

About Immunocore

Immunocore is a biotechnology company that develops targeted immunotherapies for cancer and other serious diseases. Its main technology is the ImmTAX platform, which creates soluble T cell receptor-based therapies designed to redirect the immune system to attack diseased cells. The company also has collaborations and license agreements with other parties to develop and commercialize its product candidates.

Based on the company's 10-K filed Feb 25, 2026.

Nasdaq · Healthcare

Immunocore Holdings plc (IMCR)

$31.65-0.73 (-2.25%)

BUYGrade: BRisk: MEDIUM

1D 5D1M1Y 5Y MaxSign up for all timeframes

High32.56

Low31.18

Open32.56

Volume359K

Avg Vol530K

VWAP31.70

30d High32.61

30d Low27.82

30d Chg+3.63%

See full chart with real-time data

What Is the Price Target for IMCR?

SEPT Low Target

$35.00

SEPT Mid Target

$67.50

SEPT High Target

$100.00

Analyst Consensus

$67.50

Current: $31.65Upside: +113.3%Confidence: 40%Method: Analyst Consensus

Is IMCR a Buy or Sell Right Now?

Investability Score

BUY12-18 months

News summary · last 30 days

Nov 6▲ UpEarningsProduct5 articles

Immunocore shares closed at $30.99, up 3.46% on volume of about 1.5 million shares, as investors weighed mixed news. The company reported a wider-than-expected third-quarter loss of $0.28 per share versus the $0.10 consensus, with revenue of $102.222 million missing the $113.438 million forecast. Offsetting the earnings miss, Immunocore released early-stage trial results for brenetafusp in combination with another therapy, showing a 29% overall response rate and a 71% disease control rate in a Phase 1/2 study. The bullish product data appears to have outweighed the bearish quarterly financials, pushing the stock higher on the day.

Critical news

Nov 6HIGHEarnings: decline/miss

Thesis

•Revenue growing 28.9% YoY with STRONG trend — consistent growth.

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for IMCR.

Start Free Trial →

Is IMCR Overvalued or Undervalued?

Valuation Verdict

UNDERVALUED

Methods Used

Analyst Consensus

Fair Value

$67.50

Moat Score

NONE

3/9

Piotroski Score

1.2

Altman Z-Score

What Is Smart Money Doing with IMCR?

Insider Signal

SELLING

0 buys / 4 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

HIGH

Signal: HIGH_SHORT_INTEREST

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

IMCR Growth Story

Revenue YoY

28.9%

3yr Revenue CAGR

31.9%

EPS Growth YoY

30.39%

FCF Growth YoY

-172.1%

Revenue Trend

STRONG

Dark Pool Trades for IMCR

PREVIEW

SEPT Investing tracks real-time dark pool institutional trades for IMCR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.

Time	Price	Size	Value	Side
20:50:01	$31.80	1,000	$$32K	SELL
20:24:03	$31.56	1,312	$$41K	SELL
20:02:48	$31.91	4,700	$$150K	MIDPOINT
19:52:22	$31.89	1,500	$$48K	MIDPOINT
16:27:53	$31.50	9,111	$$287K	MIDPOINT

5 dark pool trades shown · $$558K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for Immunocore Holdings plc (IMCR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (6 articles analyzed), and SEC filing intelligence...

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

IMCR — frequently asked questions

What is IMCR stock price today?

Immunocore Holdings plc (IMCR) is at $31.65, down 2.25% (-$0.73) at the Nov 11, 2026 close.

Why is IMCR stock moving today?

Latest IMCR news — Nov 11, 2026: H.C. Wainwright keeps Buy rating on Immunocore, adjusts price target · Nov 10, 2026: HC Wainwright keeps Buy rating on Immunocore, cuts price target to $80

Why did IMCR stock move on Nov 6, 2026?

What is the IMCR price target?

The average analyst price target for IMCR is $67.50, ranging from $35 to $100, based on 2 analysts.

What do analysts rate IMCR?

Analyst ratings for IMCR: 7 Buy, 4 Hold, 0 Sell — consensus Buy.

Did IMCR beat earnings?

IMCR last reported on Nov 6, 2026: EPS -$0.28 vs -$0.10 expected — a miss of 180.0%.

Does IMCR pay a dividend?

IMCR does not currently pay a dividend.

What are IMCR support and resistance levels?

Support: $31.28, $28.12. Resistance: $33.56, $35.19, $37.95.

What are insiders doing with IMCR?

Insider activity: SELLING, 0 buys and 4 sells in the last 90 days.

What is the latest news on IMCR?

Nov 11, 2026: H.C. Wainwright keeps Buy rating on Immunocore, adjusts price target · Nov 10, 2026: HC Wainwright keeps Buy rating on Immunocore, cuts price target to $80